Last Update: December 20, 2017
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
| |
|
Improvement of Oral Bioavailability of Lopinavir Without
Co-administration of Ritonavir Using Microspheres of Thiolated
Xyloglucan.
Madgulkar AR, Bhalekar MR, Kadam AA.
AA PS PharmSciTech. 2017 Jul 17.
Abstract
Comparative pharmacokinetic evaluation of lopinavir and
lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model.
Ravi PR, Vats R
J Pharm
Pharmacol. 2017 Mar 19.
Abstract
Circumvention of P-gp and MRP2 mediated efflux of lopinavir
by a histidine based dipeptide prodrug.
Mandal A, Pal D, Mitra AK .
Int J Pharm. 2016 Aug 16;512(1):49
Abstract
Bioavailability enhancement, Caco-2 cells uptake and intestinal
transport of orally administered lopinavir loaded PLGA nanoparticles.
Joshi G, Kumar A, Sawant K.
Drug Deliv. 2016 Jun 13:1-31.
Abstract
Systematic development of solid self-nanoemulsifying oily
formulations (S-SNEOFs) for enhancing the oral bioavailability and intestinal
lymphatic uptake of lopinavir.
Garg B, Katare OP, Beg S, et al
Colloids Surf B Biointerfaces.
2016 May 1;141:611-22.
Abstract
FULL-TEXT
ARTICLE
A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a
Treatment for HPV-Related Pre-Invasive Cervical Disease.
Hampson L, Maranga IO, Masinde MS, et al
PLoS One. 2016 Jan
29;11(1):e0147917.
Paper
Significant Decreases in both Total and Unbound Lopinavir and Amprenavir
Exposures during Co-administration: ACTG Protocol A5143/A5147s Results.
Dumond JB, Rigdon J, Mollan K,
et al
J Acquir Immune Defic Syndr.
2015 Jul 30.
Abstract
Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune
response triggered by Leishmania in macrophages:
The role of NFκB and PPARγ
Alves ÉA, de Miranda MG, Borges TK, et al
Int Immunopharmacol. 2014
Dec 26.
Abstract
Positioning of lopinavir/ritonavir in antiretroviral treatment
schemes.
Camacho Á, Rivero A.
Enferm Infecc Microbiol Clin.
2014 Nov;32 Suppl 3:31-4.
Abstract
Challenges of lopinavir/ritonavir in the chronicity of human
immunodeficiency virus infection
Aguirrebengoa K.
Enferm Infecc Microbiol Clin.
2014 Nov;32 Suppl 3:26-30
Abstract
Differential Subcutaneous Adipose Tissue Gene Expression Pattern with Efavirenz
or Lopinavir/ritonavir in Antiretroviral-Naïve Patients: A Randomized Clinical
Trial.
Egaña-Gorroño L, Martínez E, Domingo P, et al
Antimicrob Agents Chemother.
2014 Aug 25
Abstract
Amino Acid Prodrugs: An Approach to Improve the Absorption of
HIV-1 Protease Inhibitor, Lopinavir.
Patel M, Mandava N, Gokulgandhi M, Pal D, Mitra AK.
Pharmaceuticals (Basel). 2014 Apr
10;7(4):433-52.
Abstract
P1 and P1' para-fluoro phenyl groups show enhanced binding and
favorable predicted pharmacological properties: Structure-based virtual
screening of
extended lopinavir analogs against multi-drug resistant HIV-1
protease.
Yedidi RS, Liu Z, Kovari IA, et al
J Mol Graph Model. 2014 Feb;47:18-24.
Abstract
FULL-TEXT
ARTICLE
Kinetics of Microbial Translocation Markers in Patients on Efavirenz
or Lopinavir/r Based Antiretroviral Therapy.
Vesterbacka J, Nowak P, Barqasho B, . et
al
PLoS One.
2013;8(1):e55038.
Paper |
Surface-stabilized lopinavir nanoparticles enhance oral
bioavailability without coadministration of ritonavir.
Jain S,
Sharma JM, Jain AK, Mahajan RR.
Nanomedicine (Lond).
2013 Jan 25.
Abstract
Secondary Patenting Of Branded
Pharmaceuticals: A Case Study Of How Patents On Two HIV
Drugs
Could Be Extended For Decades.
Amin T, Kesselheim AS.
Health Aff (Millwood).
2012 Oct;31
Abstract
Impact of gag genetic determinants on virological
outcome to boosted lopinavir-containing regimen in HIV-2 infected
patients.
Larrouy L, Vivot A,
Charpentier C, et
al
AIDS. 2012 Sep 26. [
Abstract
Non-linear mixed effects modeling of antiretroviral drug response
after administration of lopinavir, atazanavir
and efavirenz
containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D, Simonsson US, Ekvall H,
et al
J Pharmacokinet Pharmacodyn.
2011 Oct 2.
Abstract
Synthesis and antimycobacterial activity of novel amino
alcohols containing central core of the
anti-HIV drugs Lopinavir and Ritonavir.
Gomes CR, Moreth M, Cardinot D, et al
Chem Biol Drug Des.
2011 Sep 20.
Abstract
Lopinavir up-regulates expression of the antiviral
protein ribonuclease L in
human papillomavirus-positive cervical carcinoma cells.
Batman G, Oliver AW, Zehbe I,
et al
Antivir Ther.
2011;16(4):515-25.
Abstract
Effect of boosted fosamprenavir or lopinavir-based combinations on
whole-body insulin
sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Randell PA, Jackson AG, Boffito M, et al
Antivir Ther.
2010;15(8):1125-1132
Abstract |
Differential Effects of Efavirenz and Lopinavir/Ritonavir on Human Adipocyte
Differentiation,Gene Expression and Release of Adipokines and Pro-Inflammatory Cytokines.
Gallego-Escuredo1 JM, Del Mar Gutierrez M, Diaz-Delfin J, et al
Curr HIV Res. 2010 Oct 1;
Abstract |
Lopinavir Loaded Solid Lipid Nanoparticles (SLN) for Intestinal
Lymphatic Targeting
Alex MR, Chacko AJ,
Jose S, Souto EB.
Eur J Pharm Sci. 2010
Oct 21.
Abstract |
Lopinavir inhibits meningioma cell proliferation by Akt
independent mechanism.
Johnson MD, O'Connell M, Pilcher W.
J Neurooncol.
2010 Jul 2.
Abstract |
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers,
but
poor substrates, of ABC transporters in a broad panel of ABC transporter-
overexpressing cell lines.
Bierman WF, Scheffer GL,
Schoonderwoerd A, et al
J Antimicrob Chemother.
2010 Jun 15
Abstract |
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the
Initial Viral Decay
Rate in Treatment Naïve HIV-1-Infected Patients.
Edén A, Andersson LM, Andersson O, et al
AIDS Res Hum Retroviruses.
2010 May 10.
Abstract |
Combining metabolic fingerprinting and footprinting to understand the
phenotypic response
of HPV16 E6 expressing cervical carcinoma cells exposed to the
HIV anti-viral
drug lopinavir.
Kim DH, Jarvis RM, Xu Y,
et al
Analyst. 2010 Apr 14.
Abstract |
The impact of SLCO1B1 polymorphisms on the plasma concentration
of lopinavir
and ritonavir in HIV-infected men.
Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G.
Br J Clin Pharmacol.
2010 Jan;69(1):95-98
Abstract |
Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in
HIV-Infected Adults
(December).
Dicenzo R,
Difrancesco R, Cruttenden K, et al
Ann Pharmacother.
2009 Nov 24
Abstract |
Plasma concentrations of generic lopinavir/ritonavir in HIV
type-1-infected individuals.
van der Lugt J, Lange J, Avihingsanon A, et a
Antivir Ther.
2009;14(7):1001-4
Abstract |
Factors influencing lopinavir and atazanavir plasma
concentration.
Stöhr W, Back D, Dunn D,
et al
J Antimicrob Chemother.
2009 Nov 6.
Abstract |
Association between ABCC2 polymorphism and lopinavir accumulation
in peripheral blood
mononuclear cells of HIV-infected patients.
Elens L, Yombi JC,
Lison D, et al
Pharmacogenomics.
2009 Oct;10(10):1589-97
Abstract |
Lopinavir co-induces insulin resistance and ER stress in human
adipocytes.
Djedaini M, Peraldi P, Drici MD,
et al
Biochem Biophys Res Commun.
2009 Jun 4
Abstract |
Binding of Lopinavir to HumanI {alpha}1-Acid Glycoprotein and
Serum Albumin.
Gulati A, Boudinot D, Gerk PM.
Drug Metab Dispos. 2009 May 13.
Abstract |
Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors
Lopinavir and Ritonavir.
Degoey DA, Grampovnik DJ, Flosi WJ, et al
J Med Chem. 2009 Apr 6.
Abstract
|
|
| |
FULL-TEXT ARTICLE
Metabolic and Neurologic Consequences of Chronic Lopinavir/Ritonavir
Administration to C57BL/6 mice
Paul J. Pistell, Sunita Gupta, Alecia G.
Antiviral Res.
2010 Dec; 88(3
Paper
Lopinavir/ritonavir enhanced the antimalarial activity of amodiaquine and
artesunate in a mouse model of Plasmodium berghei.
Abiodun OO, Gbimadee N, Gbotosho GO.
J Chemother. 2016 Feb 22:1-5
Abstract
Lopinavir/Ritonavir, an Antiretroviral Drug, Lowers Sperm
Quality and Induces Testicular Oxidative Damage in Rats.
Adaramoye OA, Akanni OO, Adewumi OM, Owumi SE.
Tokai J Exp Clin Med. 2015 Jun
20;40(2):51-7.
Abstract
FULL-TEXT ARTICLE
Neither the HIV
Protease Inhibitor Lopinavir-Ritonavir nor the Antimicrobial
Trimethoprim-Sulfamethoxazole Prevent Malaria Relapse in Plasmodium
cynomolgi-Infected Non-Human Primates.
Hobbs CV, Dixit S, Penzak SR, et al
PLoS One. 2014 Dec 26;9(12):e115506.
Paper
The effect of lopinavir/ritonavir on the antimalarial
activity of artemether or artemether/lumefantrine in a mouse model of
Plasmodium berghei.
Abiodun OO, Akinbo J, Ojurongbe O.
J Chemother. 2014 Jan
16:1973947813Y0000000158
Abstract
Prolonged exposure to lopinavir impairs endothelium-dependent
hyperpolarization-mediated relaxation in rat mesenteric arteries.
Yeung YY, Lee SS, Vanhoutte PM, Leung SW.
J Cardiovasc Pharmacol.
2013 Aug 4.
Abstract
Administration of lopinavir/ritonavir association during rat
pregnancy: maternal and fetal effects.
Kulay L Jr, Hagemann
CC, Nakamura MU
Clin Exp Obstet Gynecol.
2013;40(1):151-
Abstract
Combination Lopinavir and Ritonavir Alter Exogenous and
Endogenous Bile Acid Disposition in Sandwich-Cultured Rat Hepatocytes.
Griffin LM, Watkins PB,
Perry CH,
et
al
Drug Metab Dispos. 2012
Oct 22.
Abstract
Effect of Grapefruit Juice and Ritonavir on Pharmacokinetics of Lopinavir in
Wistar Rats.
Ravi PR, Vats R, Thakur R,
et al
Phytother Res. 2012 Feb 4.
Abstract |
Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its
Application in
Pharmacokinetic Studies.
Vats R, Murthy AN, Ravi PR.
Sci Pharm. 2011;79(4):849-863
Abstract
Mechanisms of reduced maternal and fetal lopinavir exposure in a
rat model of gestational diabetes.
Anger G, Piquette-Miller M.
Drug Metab Dispos. 2011 Jul 8
Abstract
Metabolic and Neurologic Consequences of Chronic
Lopinavir/Ritonavir Administration to
C57BL/6 mice.
Pistell
PJ, Gupta S, Knight AG, et al.
Antiviral Res.
2010 Oct 20.
Abstract |
Long term treatment by
lopinavir/ritonavir induces a reduction in peripheral
adipose deposits in mice
Prot M, Heripret L, Cardot-Leccia N, et al
Antimicrob Agents Chemother. 2006 Sep 25
Abstract |
| |
In vitro hypersusceptibility of human
immunodeficiency virus type 1 subtype C
protease to lopinavir.
Gonzalez LM, Brindeiro RM, Tarin M, et al
Antimicrob Agents Chemother. 2003 Sep;47(9):2817-22.
Abstract
|
| |
In vitro antiviral interaction of lopinavir with
other protease inhibitors.
Molla A, Mo H, Vasavanonda S, Han L
Antimicrob Agents Chemother 2002 Jul;46(7):2249-53
Abstract
|
| |
X-ray crystallographic
structure of ABT-378 (Lopinavir) bound to HIV-1 protease.
Stoll V, Qin W, Stewart KD,
Jakob C, et al
Bioorg Med Chem 2002 Aug;10(8):2803-6
Abstract |
| |
|
| |
FULL-TEXT ARTICLE
In
vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison
and metabolite identification.
Kumar GN, Jayanti V,
Lee RD, et al.
Drug Metab Dispos
1999 Jan;27(1):86-91
Paper |
| |
|
| |
Human
serum attenuates the activity of protease inhibitors toward wild-type
and
mutant human immunodeficiency virus
Molla A,
Vasavanonda S, Kumar G, Sham HL, et al.
Virology
1998 Oct 25;250(2):255-62
Abstract |
| |
|
| |
FULL-TEXT ARTICLE
In
vitro selection and characterization of human immunodeficiency virus
type 1
variants with increased resistance to ABT-378, a novel protease inhibitor.
Carrillo A, Stewart KD, Sham HL, et al.
J Virol 1998 Sep;72(9):7532-41
Paper |
| |
Physiologically
Based Pharmacokinetic Modeling
for Predicting the Effect of
Intrinsic and Extrinsic Factors
on Darunavir or Lopinavir
Exposure Coadministered With
Ritonavir.
Wagner C, Zhao P, Arya V,
et al
J Clin Pharmacol.
2017 Jun 1
Abstract
Physiologically Based Pharmacokinetic Modeling for Predicting
the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir
Exposure Coadministered With Ritonavir.
Wagner C, Zhao P, Arya V,
et al
J Clin Pharmacol. 2017 Jun 1
Abstract
Comparison of population pharmacokinetics based on
steady-state assumption versus electronically monitored adherence to
lopinavir, atazanavir, efavirenz, and etravirine: A retrospective study.
Aline F, Aurélie R, Matthias C,
et al
Ther Drug Monit. 2016 Mar 1.
Abstract
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with
lopinavir pharmacokinetics in HIV-positive adults.
Olagunju A, Schipani A, Siccardi M, et al
Pharmacogenet
Genomics. 2014 Jun 19.
Abstract
Modified pullulan nanoparticles for oral delivery of
lopinavir: Formulation and pharmacokinetic evaluation.
Ravi PR, Vats R, Balija J,
et al
Carbohydr Polym. 2014 Sep
22;110C:320-328.
Abstract
Integrated Population Pharmacokinetic/Viral Dynamic Modelling
of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients.
Wang K, D'Argenio DZ, Acosta
EP, et al
Clin Pharmacokinet. 2013 Dec 6
Abstract
Pharmacogenetic Analysis of SNPs in Genes Involved in the
Pharmacokinetics and Response to Lopinavir/Ritonavir Therapy.
López Aspiroz E, Figueroa SE,
et al
Curr Drug Metab. 2013
Sep;14(7):729-37
Abstract
Lopinavir pharmacokinetic profiles in HIV-infected patients
during rifabutin-based anti-mycobacterial therapy.
Matteelli A, Villani P,
Carvalho AC,
et
al
J Antimicrob Chemother. 2012 Jun 7.
Abstract |
Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt
Extrusion
Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers.
Schöller-Gyüre M, Kakuda TN,
et al
J Clin Pharmacol. 2012
May 1.
Abstract
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered
under different meal
conditions in HIV-infected Ugandan adults.
Lamorde M, Byakika-Kibwika P,
et al
J Acquir Immune Defic Syndr. 2012 Apr 4.
Abstract |
Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in
HIV-Infected Patients.
Aspiroz EL, Buelga DS, Figueroa SC,
et al
Ther Drug Monit. 2011 Sep 10.
Abstract
The pharmacokinetics of lopinavir in HIV-infected adults
receiving rifampicin with adjusted doses of
lopinavir/ritonavir tablets.
Decloedt EH,
McIlleron H, Smith P,
et al
Antimicrob Agents Chemother.
2011 May 2.
Abstract
Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected
Women and Men.
Umeh OC, Currier JS, Park JG, et al
J Clin Pharmacol.
2011 Jan 13
Abstract |
An integrated pharmacokinetic model for the influence of CYP3A4 expression on
the in vivo
disposition of lopinavir
and its modulation by ritonavir.
Heine RT, Van Waterschoot RA, Keizer RJ, et al
J Pharm Sci. 2010 Dec 29
Abstract |
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of
400/100 mg,
200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
Jackson A, Hill A, Puls R, Else L,
et
al
J Antimicrob Chemother. 2010 Dec
17
Abstract |
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir
trough
concentrations in HIV-infected patients.
Calza L, Mosca L, Pocaterra D,
et al
Eur J Clin Pharmacol.
2010 Sep 28.
Abstract |
Effects of cytochrome P450 3A (CYP3A) and the drug transporters
P-glycoprotein
(MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA, Ter Heine R, Wagenaar E,et al
Br J Pharmacol.
2010 Jul;160(5):1224-33.
Abstract |
Pharmacokinetics of Lopinavir./Ritonavir with and without
Non-Nucleoside
Reverse Transcript Inhibitors in Ugandan HIV-Infected Adults
Kityo C, Walker AS, Dickinson L, et al
Antimicrob Agents Chemother.
2010 Apr 26
Abstract |
ADME pharmacogenetics: investigation of the pharmacokinetics of the
antiretroviral
agent lopinavir coformulated with ritonavir.
Lubomirov R, di Iulio J, Fayet A, et al
Pharmacogenet Genomics.
2010 Feb 4.
Abstract |
A population analysis of weight-related differences in
lopinavir pharmacokinetics and possible consequences for protease
inhibitor-naive and -experienced patients.
Bouillon-Pichault M, Jullien V, Piketty C, et al
Antivir Ther.
2009;14(7):923-9
Abstract |
Lopinavir/Ritonavir pharmacokinetics in a substitution of high-dose
soft-gelatin capsule to tablet formulation.
Hull MW, Harris M, Lima V,
et al
J Clin Pharmacol.
2009 Feb;49(2):155-61.
Abstract
|
Human Immunodeficiency Virus Type 1 Genotypic and
Pharmacokinetic
Determinants of the Virological Response to
Lopinavir-Ritonavir-Containing
Therapy in Protease
Inhibitor-Experienced Patients.
Masquelier B, Breilh D, Neau D, et al.
Antimicrob Agents Chemother 2002 Sep;46(9):2926-2932
Abstract
Pharmacokinetics of amprenavir and lopinavir in combination with
nevirapine
in highly pretreated HIV-infected patients.
Fãtkenheuer G, Römer K, Kamps
R, et al
AIDS, 2001:Vol 15, No 17 2334-2355
Abstract
ABT 378/r: a novel inhibitor of HIV-1 protease in
haemodialysis.
Izzedine H, Launay-Vacher V, Legrand M, et al.
AIDS 2001 Mar 30;15(5):662-4
Abstract
FULL-TEXT ARTICLE
Potent
inhibition of the cytochrome P-450 3A-mediated human liver
microsomal
metabolism
of a novel HIV protease inhibitor by ritonavir:
A positive drug-drug
interaction.
Kumar GN, Dykstra J, Roberts EM, Jayanti
VK, Hickman D, et al.
Drug Metab Dispos 1999 Aug;27(8):902-8
Paper
FULL-TEXT ARTICLE
ABT-378,
a highly potent inhibitor of the human immunodeficiency virus
protease.
Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al
Antimicrob Agents
Chemother 1998 Dec;42(12):3218-24
Paper
FULL-TEXT ARTICLE
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency
virus protease by coadministration with ritonavir.
Kempf DJ, Marsh KC, Kumar G, et al;
Antimicrob Agents Chemother
1997 Mar;41(3):654-60
Paper
|
|
| |
Quantification of cell-associated atazanavir,
darunavir, lopinavir, ritonavir, and efavirenz concentrations in
human mononuclear cell extracts.
Podany AT, Winchester LC, Robbins BL, Fletcher CV.
Antimicrob Agents Chemother. 2014
May;58(5):2866-70
Abstract
Evidence-based Therapeutic Drug Monitoring of lopinavir
Barrail-Tran A, Taburet AM, Poirier JM.
Therapie. 2011
May-Jun;66(3):231-8
Abstract
The relation between treatment outcome and efavirenz, atazanavir or
lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected
patients.
Josephson F, Andersson MC, Flamholc L, et al
Eur J Clin Pharmacol.
2009 Dec 5.
Abstract |
Identification of new genotypic cut-off levels to predict the efficacy
of lopinavir/ritonavir and
darunavir/ritonavir in the TITAN trial.
Hill A, Marcelin AG, Calvez V.
HIV Med. 2009
Jul 6.
Abstract |
Predictive value of the HIV phenotype and genotype and of amprenavir and
lopinavir inhibitory
quotients in heavily pretreated patients on a ritonavir-boosted dual
protease inhibitor regimen.
Barrail-Tran A, Morand-Joubert L, Poizat G, et al
Antimicrob Agents Chemother.
2008 Feb 19
Abstract
|
Drug monitoring and viral response to
Lopinavir/Ritonavir or Saquinavir/Ritonavir
containing regimens in individuals infected with the human immunodeficiency
virus type 1
Falkensammer B, Fasser W, Scherer K, et al
Int J Immunopathol Pharmacol. 2005
January-March;18(1):145-154
Abstract
Therapeutic drug monitoring of lopinavir/ritonavir given
alone or with a
non-nucleoside reverse transcriptase inhibitor.
Solas C, Poizot-Martin I, Drogoul MP, et al
r J Clin Pharmacol. 2004 Apr;57(4):436-40.
Abstract
|
| |
Durability of lopinavir/ritonavir dual-therapies in individuals
with viral load <50 copies/mL in the observational setting.
Gianotti N, Cozzi-Lepri A, Antinori A. et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19799.
Abstract
FULL-TEXT ARTICLE
Phenotypic characterization of virological failure following lopinavir/ritonavir
monotherapy using full-length gag-protease genes.
Sutherland KA, Mbisa JL, Ghosn J, et al
J
Antimicrob Chemother. 2014 Aug 4.
Paper
Virological characterization of patients failing darunavir/ritonavir or
lopinavir/ritonavir treatment in
the ARTEMIS study:96-week analysis.
Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T,
et al
Antivir Ther.
2011;16(1):99-108
Abstract
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the
Initial Viral Decay
Rate in Treatment Naïve HIV-1-Infected Patients.
Edén A, Andersson LM, Andersson O, et al
AIDS Res Hum Retroviruses.
2010 May 10.
Abstract |
Virologic Response to Lopinavir/Ritonavir-Based Antiretroviral Regimens in a
Multi-Center International Clinical Cohort:
Comparison of Genotypic Interpretation Scores.
Grant P, Wong EC, Rode R, et al
Antimicrob Agents Chemother. 2008 Aug 18.
Abstract
|
FULL-TEXT PDF
ARTICLE
Differences in the detection of three HIV-1 protease inhibitors in
non-blood
compartments: clinical correlations.
Lafeuillade A, Solas C, Halfon P, et al.
HIV Clin Trials 2002
Jan-Feb;3(1):27-35
Paper |
| |
|
| |
Identification
of Genotypic Changes in Human Immunodeficiency Virus Protease
that Correlate with Reduced Susceptibility to the Protease
Inhibitor Lopinavir
among Viral Isolates from Protease
Inhibitor-Experienced Patients.
Kempf DJ, Isaacson JD, King MS, et al.
J Virol. 2001 Aug;75(16):7462-9.
Abstract |
|
KLS
Main Page
Main
New/Newsworthy
